CHRS
Coherus Oncology, Inc. Common Stock
stockNASDAQ
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.77 | 2026-11-06 | -32.13% | 6.849 |
| 1M | 1.07 | 2026-10-13 | -51.16% | 2.956 |
| 3M | 1.14 | 2026-08-13 | -54.16% | 2.084 |
| 6M | 1.71 | 2026-05-13 | -69.35% | 1.690 |
| 1Y | 1.26 | 2025-11-13 | -58.52% | 1.967 |
| 2Y | 0.78 | 2024-11-13 | -32.89% | — |
| 5Y | 18.62 | 2021-11-12 | -97.19% | 1.635 |
Coherus Oncology, Inc. Common Stock (NASDAQ:CHRS) stock price today is $0.52, and today's volume is 4,306,287. CHRS is down 2.953% today. The 30 day average volume is 2.02M. CHRS market cap is $80.74M with 154.50M shares outstanding.